Premium
Transitional cell carcinoma expresses high levels of Fas ligand in vivo
Author(s) -
Myeong Soo Lee,
Myeong Soo Lee,
HaeSim Park,
Ki Wook Kim,
Jang ,
Ji-Sang Yoo
Publication year - 1999
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1046/j.1464-410x.1999.00975.x
Subject(s) - in vivo , ligand (biochemistry) , fas ligand , cancer research , microbiology and biotechnology , chemistry , biology , apoptosis , receptor , genetics , programmed cell death , biochemistry
Objective To characterize the Fas‐Fas ligand system, a main apoptotic pathway, in transitional cell carcinoma (TCC) of the urinary bladder, by analysing the expression of Fas and Fas ligand (FasL) in TCC samples. Materials and methods Archival paraffin‐embedded tissues from 37 patients with TCC were analysed by immunohistochemistry to determine Fas and FasL expression. Results Fas and FasL were detected on the cell surface and cytoplasm of respectively 34 (92%) and all cases analysed. The expression of Fas and FasL did not differ with the cytological grade of TCC. Conclusion The high expression of FasL in TCC, reported for the first time in the present study, suggests that FasL may contribute to the immune escape of TCC through killing Fas‐bearing lymphocytes. Co‐expression of Fas with FasL also suggests that TCC may have pathways resistant to Fas‐mediated autocrine cell suicide.